Eisai invests in BioArctic's Alzheimer research
Japanese firm inputs world-leading know-how in next-generation treatment
This licence deal will safeguard BioArctic's existence and R&D activities for a number of years, according to BioArctic's CEO, Pär Gellerfors. The deal will also give BioArctic the possibility to develop their other projects quicker and more securely as it now employs people to run R&D in-house. The R&D expenditure and risk for this project will be shared between the two firms.
"We are very pleased with this collaboration with Eisai, which is the world-leading pharmaceutical company in Alzheimer's Disease research. Since we work with a totally new concept for the treatment of this severe disease, we want to have a strong and long-lasting relationship with a partner that is fully committed to take this exciting project all the way to the market," Gellerfors said.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.